lna-i-mir-221
Nucleic acidexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 14, 2019 (NCT04811898)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Cereblon/Apoptosis-stimulating of p53 protein 2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04811898 | Phase 1 | Jan 14, 2019 | Associazione Italiana per la Ricerca sul Cancro, Magna Graecia University, University of Catanzaro |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Associazione Italiana per la Ricerca sul Cancro | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Magna Graecia University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Catanzaro | Academic/Hospital | 1 | 1 | 1 | 2019 |
3 organizations
Page 1 / 1